Age and comorbidities can impact on the success of handling an inhaler. In this pilot study, we assessed finger strength in 62 participants (aged 5-17 years [n = 20], 18-65 years [n = 22] and > 65 years [n = 20]) by using different types of inhalers with integrated sensors (Respimat®, Breezhaler®, Aerolizer®, Genuair®, Diskus®, Ellipta®, HandiHaler®, Turbohaler® and a pressurized metered-dose inhaler [Atrovent®]). Parameters under investigation included the spontaneous and maximum achievable force and torque required to operate devices. Satisfaction with individual inhalers, and the relationship between satisfaction and strength, were also assessed. There was a marked difference in the compressive force required to operate individual inhalers, with maximum values ranging between 0.7 N and 39 N. Finger strength differed considerably between age groups, and participants with rheumatic disease showed different preferences and experienced more difficulties compared with healthy subjects. Satisfaction between devices was highly variable, and influenced by comorbidities and the ability to understand user instructions. Our findings suggest that individual patients' circumstances need to be considered when prescribing an inhaler and may help in the development of future devices, leading to design options with increased ease of operation.
Introduction
A medical device should be suitable for all patients, regardless of their age and physical ability; however, physical constraints, such as impaired vision, reduced manual dexterity or strength, and loss of touch and sensitivity in the hands, can interfere with the user's ability to interact with the product and may cause use problems (Notenboom et al., 2017) . Handling strength and manual dexterity can have a significant impact on the appropriate use of medication; for instance, older adults may experience difficulties with tamper-proof container caps and blister packaging (Notenboom et al., 2017) .
The use of inhaled medication is a central component in the management of asthma and chronic obstructive pulmonary disease (COPD) (Braido et al., 2016; Yawn et al., 2012 ), yet up to 94% of patients with asthma or COPD have been found to not handle their inhalers appropriately (Jahedi et al., 2017) . Correct inhaler technique is important for optimal delivery of drug to the lungs, leading to clinical improvements and the achievement of disease control . A wide selection of inhaler devices is available, including pressurized metereddose inhalers (pMDIs), breath-actuated pressurized metered-dose inhalers, dry powder inhalers (DPIs) or soft mist inhalers (Braido et al., 2016) . Each class of device takes a different approach to inhalation, but also presents its own challenges regarding ease of use of the device, technique and patient factors.
An appropriate choice of inhaler device can help enhance patient satisfaction, treatment adherence and long-term outcomes (Braido et al., 2016; Dudvarski Ilic et al., 2016; Small et al., 2011; Virchow et al., 2015) , but needs to be tailored to individual needs and consider patient suitability, individual preferences and limitations (Braido et al., 2016; Miravitlles et al., 2016) . Specific factors for consideration include inhalation speed, age, cognitive ability and visual acuity Rogliani et al., 2017; Yawn et al., 2012) . In addition, successful inhaler utilization depends on coordination (the ability of patients to synchronize inhalation and aerosol release), manual strength and dexterity, and finger strength is also an important component (Rogliani et al., 2017; Yawn et al., 2012) . It has been suggested that handgrip strength should be monitored on a regular basis to check whether the prescribed inhaler is still suitable for a patient, and ideally, inhalers should not be used by patients with a handgrip strength of less than 100 Newtons (N) to reduce non-compliance (Frohnhofen and Hagen, 2011) .
Children, the elderly and those with conditions that may impact on handgrip and manual dexterity may need particular consideration to ensure selection of the most appropriate inhaler. In young children, successful inhaler use depends on cooperation, the technical properties of the inhalation device and the ability of the child to perform a correct inhalation manoeuvre with the device (Kamin et al., 2015; Walsh et al., 2011) . In older patients, the presence of arthritis, a common comorbidity of COPD, or joint pain can be a contributing factor to a patient's inability to correctly use a handheld inhaler device (Taffet et al., 2014; Yawn et al., 2012) .
The aim of this unique study was to provide quantitative force data to investigate whether finger strength is a factor in the difficulty children, the elderly and patients with rheumatic diseases may experience when handling different types of inhalers. Satisfaction with a selection of inhaler devices was also investigated.
Material and methods

Study participants
This was a pilot study involving participants with a minimum age of 5 years. Participants or their legally responsible persons (e.g. parents) were also given information about the study, including safety considerations, potential risks, and instructions on how to operate inhalers equipped with a force or torque sensor. All participants or their legally responsible persons provided written consent to take part in the study.
Participants were excluded from the study if they suffered from any serious illness that may preclude them from successfully completing the tasks, if their ability to consent was impaired, or if they or their legally responsible persons refused consent. Study participants aged 7-17 years were provided with age-appropriate information on the study details, which they were required to sign. In the case of children younger than 7 years who could not yet read, the information was read out loud for them while their parents were present. Both inhaler-experienced and inhaler-naïve patients were included in the study.
Materials
The following commercially available inhalers were investigated: Respimat® (Boehringer Ingelheim, Ingelheim, Germany), Breezhaler® (Novartis, Basel, Switzerland), Aerolizer® (Novartis, Basel, Switzerland), Genuair® (Almirall, Barcelona, Spain), Diskus® (GlaxoSmithKline, London, UK), Ellipta® (GlaxoSmithKline, London, UK), HandiHaler® (Boehringer Ingelheim, Ingelheim, Germany), Turbohaler® (AstraZeneca, Cambridge, UK) and the Atrovent® inhalation aerosol (a pMDI; Boehringer Ingelheim, Ingelheim, Germany). Inhalers were empty, meaning that no clinical effects were investigated.
Study procedures
Measurements were taken at participants' homes or places of work at their preferred time of day. Participants were asked to operate the inhaler, e.g. to push the release button of each inhaler using the level of force they would spontaneously apply to an inhaler, remote control or similar device. Subsequently, they were asked to push the button as hard as possible, but not to the extent that discomfort or pain was felt. Where appropriate (Diskus®, Ellipta®, Turbohaler®, Respimat®), participants were requested to spontaneously turn or pull on the inhaler, a dedicated lever or the cap as hard as possible without inflicting discomfort or pain. All measurements were carried out in triplicate. If participants misunderstood instructions or had difficulties with the handling, single measurements were repeated up to three times and any difficulties were recorded.
Parameters under investigation included the spontaneous and maximum achievable force required to press the release button of the Respimat®, Breezhaler®, Aerolizer®, Genuair®, HandiHaler® and the pMDI. For the Diskus® and Ellipta®, the force required to slide the lever or slide the cover that transport the internal blister strip was measured. The compressive force required to operate each inhaler was measured with a force sensor (Mecmesin, Schwenningen, Germany). The spontaneous and maximum achievable force to remove the transparent base of the Respimat® by pulling it was also measured with such a force sensor (Mecmesin, Schwenningen, Germany).
The spontaneous and maximum achievable torque to turn the Respimat® or Turbohaler® was investigated with a torque tester (Mecmesin, Schwenningen, Germany).
To measure finger strength, the sensors were incorporated at the position of the release button, depending on the individual device design. It was investigated whether the required strength/torque to operate the inhalers was surpassed by the study subjects.
Satisfaction with the individual inhalers, and the relationship between satisfaction and strength, were also assessed. For this, participants were requested to fill in a questionnaire after completing the strength tests, indicating how satisfied they were with the use of the inhalers (the questionnaire is shown in the supplementary materials). Answers were on a scale of 1-5 for each device (1 = not satisfied; 2 = somewhat unsatisfied; 3 = neither satisfied nor unsatisfied; 4 = somewhat satisfied; 5 = very satisfied).
Statistical analyses
This was a pilot study, so no formal sample size calculations were performed. It was assumed that a minimum of 60 participants (n = 20 for each of the included age groups; 5-17 years, 18-65 years, > 65 years) would be adequate to gather sufficient information from the testing procedures. Due to the pilot nature of the study, no statistical tests were conducted and no prior assumptions regarding effect or variability of results were made. Descriptive statistics were used to analyse measurements. Abbreviations: N, Newton; Nm, Newton meter; SD, standard deviation. * Included patients aged 42-83 years, participants with arthritis/arthrosis are also included in the Adults and Elderly Groups. ** Graded as follows: 1 = very weak, 2 = somewhat weak; 3 = average; 4 = above average strong; 5 = top strength (sportsman equivalent).
Results
Demographics and health status of study participants
The study included 62 participants (32 female, 30 male) (Table 1) . Participants were aged 5-17 years (n = 20), 18-64 years (n = 22) or ≥ 65 years (n = 20). Health conditions and comorbidities included asthma or previous asthma (n = 5), arthritis and/or rheumatism (n = 3), developmental delays (n = 1), dementia (n = 1), diabetes type 1 (n = 1), arthrosis (n = 3) and COPD (n = 2). One participant had previous surgery on their thumb and another patient experienced pain in their thumb; another had previously had a venous thrombosis and pulmonary embolism. One patient experienced pain in their knees. One patient had undergone heart bypass surgery, suffered from heart failure and experienced difficulty breathing.
Force required to operate inhalation devices and finger force
There was a marked difference in the compressive force required to operate the inhalers tested, with maximum values ranging from 0.7 N (force required to slide the lever of the Diskus®) to 32 N (force required to pierce the capsule of the Aerolizer®) and 39 N (force required to push down the cartridge in the pMDI; Table 2 ). Forces applied by patients with arthritis were similar to those of children, whereas adults exerted a higher mean force for all inhalers ( Table 2 ). The highest mean force in all groups was measured with the pMDI. Schematic representations of the observed hand and finger positions of the participants are shown in Fig. 1. Fig. 2 shows the number of participants with sufficient and insufficient force to operate an inhalation device by age group.
All participants managed to exercise the force required to operate the Genuair® and Diskus®, and to remove the cap of the Respimat®. The Aerolizer® and the pMDI were the most difficult devices to operate for children, with eight children per device not being able to exercise the required force. For the elderly, the Aerolizer®, Ellipta®, pMDI and Turbohaler® were the most difficult devices to operate. Amongst the adults, four counts of insufficient strength to operate an inhaler were observed: for the Aerolizer®, Breezhaler®, the pMDI (all the same participant) and the Ellipta® (a further participant).
Overall, it was noticeable that using the thumb resulted in a higher force being applied compared with the index or middle finger. The trace of an example force measurement is shown in Fig. 3 . The trace shows three measurements of the patient intuitively pressing the button of an inhaler (in this example the HandiHaler®) and three measurements with them pressing it with full force.
Participant satisfaction
Satisfaction with inhalation devices varied between participants (Fig. 4) . Ellipta® was rated worst and the pMDI received the best ratings; the difference in satisfaction between these two inhalers was statistically significant (P < 0.001).
Satisfaction was not statistically different for the pMDI and Respimat® (push button action; P = 0.305). The difference in satisfaction with the two inhalers which required torque (Turbohaler® and Respimat®) was statistically significant (P = 0.015), with all preferring Respimat® in relation to design.
Almost all participants expressed irritation that, except for the pMDI, the inhaler buttons did not move once pressed, meaning that no feedback was felt. Difficulties with understanding user instructions were most frequently observed with the Diskus® (in four participants), since the photograph in the user manual was found hard to interpret. Children found it easier to understand graphic instructions compared with older participants. At times, inhalers were erroneously held upside-down by participants. Occasional difficulties in operating devices were observed with Ellipta® (n = 2), the pMDI (n = 2), Turbohaler® (n = 2) and Respimat® button (n = 1), in turning the Respimat® (n = 1) and in removing the Respimat® transparent base (n = 1). Participants noted discomfort when using the small and round buttons of the Breezhaler®, Turbohaler® and Diskus®. In addition, pressing the Diskus® lever was considered uncomfortable due to its sharp edges.
Participants with arthritis reported that hand positions requiring fingers to be moved close together (as necessary for the Breezhaler® and Turbohaler®) were more painful than positions allowing the thumb and other four fingers to be further apart. In general, children preferred smaller inhalers (such as the Breezhaler®); adults and the elderly preferred larger devices.
Discussion
In this pilot study, differences in the strength required to operate the individual inhalers and in the finger strength of the three groups investigated (children, adults and the elderly) were identified. The minimum force to operate inhalers varied from 0.7 N (Diskus®) to 39 N (pMDI).
The unique feature of this handling study is that it provides quantitative force data, as is required in the design and technical evaluation of new inhalation devices. For that purpose, several inhalers were disassembled and a force or torque sensor inserted to provide quantitative actuation data. Our study differs from other handling studies where device preference was tested as a way of assessing handling, or where Table 2 Required force (N) and torque (Nm) required to operate the inhalers and mean maximum forces applied by study participants.
Inhaler
Mean required force, N ± SD (min, max) Mean measured maximum force by study subject group, N ± SD Abbreviations: N, Newton; Nm, Newton meter; pMDI, pressurized metered-dose inhaler; SD, standard deviation. * Included patients aged 42-83 years.
handling errors and close calls were counted, providing only pass/fail information. Since strength to operate an inhaler is an essential part in the success of this type of therapy, choosing the appropriate inhaler is particularly critical for children, the elderly and patients with conditions that may impact on finger strength. Although healthy adults in our study had sufficient strength to operate most inhalers, not all children, elderly adults (> 65 years) and participants with arthritis could exercise the required force. This is an important consideration in cases of a first prescription or a change in prescription, where it may be necessary to determine whether the new device is suitable for the patient.
In our study, it was noted that the strength of patients with arthritis or arthrosis was comparable with that in children, with both groups achieving markedly lower values than healthy adults. Arthritis often affects the finger joints, meaning that certain handling manoeuvres, such as bringing the thumb together closely with the opposite fingers, can be very painful. This movement is required when handling the Breezhaler® and Turbohaler®, and unsurprisingly, both devices scored relatively low for satisfaction in patients with arthritis in our study. For patients with arthritis, it is more acceptable to move the entire hand, instead of just individual fingers, or to keep the thumb and opposite finger in relatively wide separation to each other, as would be the case when handling, for example, a pMDI.
Lower finger strength was also observed in participants with heart failure, type 1 diabetes and delayed development in children. These conditions have been associated with weaker muscle strength and handgrip previously. Relative muscle power and force have been shown to be decreased in adolescents with type 1 diabetes (Maratova et al., 2017) . Chronic heart failure is associated with alterations on skeletal muscle morphology, metabolism, blood flow and function (Piepoli and Crisafulli, 2014) , and elderly patients with heart failure have been shown to experience a gradual decrease in handgrip strength (CadenaSanabria and Velandia-Carillo, 2017) . There is a direct relationship between the body height and strength-generation capacity of children, and muscle strength, including handgrip, is highly dependent on height (Hogrel et al., 2012) .
Elderly study participants had more difficulties in understanding operating instructions compared with children and adults, and often needed repeated explanation on how to handle a device. This varied between devices and was largely dependent on the graphic illustrations in the operating manuals. If it was clear from the instruction where exactly a patient had to press, turn or pull, fewer difficulties were experienced. Our results agree with Takaku et al., who evaluated the number of instructions that are necessary to minimize errors in using pMDIs, soft mist inhalers (Respimat®) and DPIs (Takaku et al., 2017) . They showed that at least three instructions were required for every device to achieve entirely no errors or less than 10% errors in total. The most common error on the use of pMDIs was device handling, whereas that of DPIs was inhalation manner. The authors concluded that it is necessary to repeat instructions at least three times to achieve effective inhalation skills in both asthma and COPD patients. This should be an important consideration for manufacturers when creating illustrations for operating manuals (Braido et al., 2016; Yawn et al., 2012) .
A study by Dal Negro et al. assessed and compared the acceptance and cost of patients' training for proper usability of Breezhaler® and Genuair® (both DPIs) and Respimat® (a soft mist inhaler) in outpatients with asthma and COPD (Dal Negro and Povero, 2016) . In the study, Genuair® and Respimat® were perceived by patients and healthcare professionals as the easiest devices to use, while Breezhaler® required the highest number of attempts for achieving the first proper actuation. The costs to train patients to use their inhalation device properly was 3-4 times higher for Breezhaler® compared with Genuair® or Respimat®. Their study supports our findings that there are big differences in the acceptance and handling of inhalers between patients. In our study, subjective satisfaction with the shape of the inhaler and release buttons was similar to the results of Dal Negro and Povero between these three devices.
Possible limitations of our study are that all measurements for one subject's strength were conducted on the same day and at the same time point. It is possible that study subjects may have performed differently if the measurements had been carried out at a different time of day or a different day altogether. Also, the environment in which measurements were carried out was not standardized, as patients were visited in their homes or at their place of work. Differences in the environment (such as different noise levels) may have provided distraction and, therefore, could have impacted on the test results. Furthermore, it cannot be excluded that a participant may have had the required strength to operate a device, but pressed the sensor at an unfavourable angle. Unlike with dummy devices, when handling the commercially available inhalers, patients would probably notice this mistake and adapt the angle accordingly. All but one of the inhalers were presented with buttons and/ or operating elements in a fixed position. The flexible design of the pMDI with a sensor led to fast positive feedback after pressing the button. This may have artificially lowered the results of the forces measured for this inhaler type in the spontaneous mode. The impact of this type of flexible design should be investigated in a future study.
Conclusions
In conclusion, we noted considerable differences in the handling of different inhalers due to the finger strength required for their operation. Finger strength also differed considerably between test groups, with patients with arthritis showing different preferences and experiencing more difficulties compared with healthy subjects. When prescribing an inhaler, a patient's age, coordination, cognitive abilities, comorbidities and finger strength should be considered. Our pilot study provides a Fig. 2 . Ability of study participants to exercise the required force or torque to operate an inhalation device. Abbreviation: pMDI, pressurized metered-dose inhaler. Fig. 3 . Example trace, derived by the study subject pressing the button three times intuitively and three times with their full power. Abbreviation: N, Newton.
rationale for future studies with larger numbers of study subjects, including patients with arthritis. Our experimental design incorporating sensors could also be extended to other devices, such as auto-injectors used for the treatment of arthritis. Our findings may help in the development of future devices, leading to design options with increased ease of operation.
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